Active Frontline Stocks in Broker Choice: Northwest Biotherapeutics, Inc. (NASDAQ:NWBO), Curis, Inc. (NASDAQ:CRIS)

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) [Trend Analysis] retains strong position in active trade, as shares scoring -28.35% to $0.35 in a active trade session, while looking at the shares volume, around 14.2 Million shares have changed hands in this session. Northwest Biotherapeutics (NWBO) announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $10 million.

The Company will sell to the investors approximately 28.6 million shares of common stock at a purchase price of $.35 per share resulting in gross proceeds to the Company of $10 million.  The investors will also receive warrants to purchase up to approximately 14.3 million shares of common stock with an exercise price of $.35 per share and an exercise period of 5 years.

The firm has institutional ownership of 29.70%, while insider ownership included 30.22%. NWBO attains analyst recommendation of 2.00 with week’s performance of -21.65%.

Curis, Inc. (NASDAQ:CRIS) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 11.76% to 3.42 with around 2.56 Million shares have changed hands in this session. Finally, analysts shed their light over the CRIS price targets; maintaining price high target of 8.00 while at average the price target was 6.67 in contrast with the current price of 3.41. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.

So does the rankings given by analysts; let us highlight rankings table and we had 3 analysts recommending BUY ratings for current month and for previous month 4 stands on similar situation; while 0 for the current month as compared to 0 analysts recommending for HOLD from the pool for previous month. While 1 stands at overweightand 0 out of pool consider it as Sell for current month. For the overall, consensus ratings were for Buy.

The stock is going forward its fifty-two week low with 173.60% and lagging behind from its 52-week high price with -8.06%. Similar, the positive performance for the quarter recorded as 29.11% and for the year was 2.34%, while the YTD performance remained at 5.15%. CRIS has Average True Range for 14 days of 0.22.

 

About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *